Current Aspects of the Bronchopulmonary Dysplasia Problem in Newborns
Keywords:
bronchopulmonary dysplasia, definition, consequences, pathogenetic mechanisms, prevention, treatment, prematurityAbstract
Bronchopulmonary dysplasia (BPD) remains important cause of morbidity of very premature infants significantly affecting their long-term outcomes. Despite the all developments and latest advances in perinatal medicine the incidence of BPD has not decreased much during the last decades. Significant changes in BPD definition, pathology, pathophysiology, clinical course, radiological findings and management have occurred over the last 40 years. After many years of intensive and extensive investigations aimed to study mechanisms of BPD development and elaborate effective methods of its prevention and treatment, there is a discouraging paucity of proven safe and beneficial therapies to prevent or limit the severity of BPD. Additional studies of respiratory technologies, management strategies, and protective molecules are needed.
Downloads
References
Northway WH, Rosan RC, Porter DY. Pulmonary disease following respiratory therapy of hyaline-membrane disease: bronchopulmonary dysplasia. N Engl J Med 1967;276:357–368.
Bonikos DS, Bensch KG, Ludwin SK, Northway WH. Oxygen toxicity in the newborn: the effect of prolonged 100% O2 exposure in the lungs of newborn mice. Lab Invest 1975;32:619–635.
Bancalari E. Changes in the pathogenesis and prevention of chronic lung disease of prematurity. Am J Perinatol 2001;18:1–9.
Charafeddine L, D’Angio CT, Phelps DL. Atypical chronic lung disease patterns in neonates. Pediatrics 1999;103:759–765.
Jobe AH. The new BPD: an arrest of lung development. Pediatr Res 1999; 46: 641–643.
Coalson JJ. Pathology of new bronchopulmonary dysplasia. Semin Neonatol 2003;8:73–81.
Bancalari E, Claure N, Sosenko IRS. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin Neonatol 2003; 8, 63–71.
Tooley WH. Epidemiology of bronchopulmonary dysplasia. J Pediatr 1979;95:851–858.
Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988;82:527–532.
Davis PG, Thorpe K, Roberts R, Schmidt B, Doyle LW, Kirpalani H. Trial Indomethacin Prophylaxis in Preterms Investigators: evaluating ‘‘old’’ definitions for the ‘‘new’’ bronchopulmonary dysplasia. J Pediatr 2002;140: 555–560.
Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723–1729.
Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol 2003;23:451–456.
Jobe AH. The new BPD. NeoReviews 2006;7:e531.
The Official Statement of the American Thoracic Society as approved by the ATS Board of Directors, December 2002. Statement on the care of the child with chronic lung disease of infancy and childhood. Am J Respir Crit Care Med 2003;168:356–396.
Smith VC, Zupancic JAF, McCormick, MC, Croen LA, Greene J, Escobar GJ, Richardson DK. Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. J Pediatr 2005;146:469–473.
Fanaroff AA, Stoll BJ, Wright LL, et al; NICHD Neonatal Research Network. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007;196:147.e1-147.e8.
Greenough A, Alexander J, Burgess S et al. High versus restricted use of home oxygen therapy, health care utilisation and the cost of care in chronic lung disease infants. Eur J Pediatr 2004; 163: 292–296.
Greenough A. Measuring respiratory outcome. Semin Neonatol 2000; 5: 119–126.
Greenough A, Alexander J, Burgess S et al. Health care utilisation of chronic lung disease infants related to hospitalisation for respiratory syncytial virus infection. Arch Dis Child 2001; 85: 463–468.
Greenough A, Alexander J, Burgess S, Chetcuti PAJ, Cox S, Lenney W, Turnbull F, Shaw NJ, Woods A, Boorman J, Coles S, Turner J. Home oxygen status on rehospitalisation and primary care requirements of chronic lung disease infants. Arch Dis Child 2002; 86:40–43.
Baraldi E, Filippone M, Trevisanuto D, Zanardo V, Zacchello F. Pulmonary function until two years of life in infants with bronchopulmonary dysplasia. Am J Respir Crit Care Med 1997; 155: 149–155.
Greenough A. Bronchopulmonary dysplasia – long term follow up. Paediatr Resp Rev 2006; 7S:S189–S191.
Greenough A, Dimtiriou G, Bhat RY, Broughton S, Hannam S, Rafferty GF, Leipala JA. Lung volumes in infants who had mild to moderate bronchopulmonary dysplasia. Eur J Pediatrics 2005; 164: 583–586.
Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA. 2003;289:1124–1129.
Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet 2006; 367:1421–1431.
Bhandari V., Bizzarro MJ, Shetty AH. Familial and genetic susceptibility to major neonatal morbidities in preterm twins. Pediatrics 2006;117:1901–1906.
Thomas W, Speer CP. Prevention and treatment of bronchopulmonary dysplasia: current status and future prospects. J Perinat 2007;27:S26–S32.
Darlow BA, Graham PJ. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev 2002; 4: doi:10.1002/14651858.CD000501.
Walsh M, Laptook A, Kazzi SN, Engle WA; NICHD Neonatal Network. A cluster-randomized trial of benchmarking and multimodal quality improvement to improve survival free of bronchopulmonary dysplasia in infants less than 1250 grams birth weight. Pediatrics. 2007;119: 876–890.
Polin RA, Sahni R. Newer experience with CPAP. Semin Neonatol 2002;7:379–389.
Henderson-Smart DJ, Bhuta T, Cools F, Offringa M: Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. Cochrane Database Syst Rev 2003: CD000104.
Bhuta T, Henderson-Smart DJ: Elective high frequency jet ventilation versus conventional ventilation for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2000:CD000328.
McCallion N, Davis PG, Morley CJ: Volume-targeted versus pressure-limited ventilation in the neonate. Cochrane Database Syst Rev 2005:CD003666.
Kinsella JP, Abman SH. Inhaled nitric oxide in the premature newborn. J Pediatr 2007;151:10–15.
The STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial, I: primary outcomes. Pediatrics 2000;105:295–310.
The STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial, I: primary outcomes. Pediatrics 2000;105:295–310.
Egberts J, Brand R, Walti H, Bevilacqua G, Breart G, Gardini F. Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Pediatrics 1997;100:E4.
Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 h) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1: doi:10.1002/14651858.CD001146.
Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1: CD001145.
Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7–14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1; doi:10.1002/14651858.CD001144.
Shah SS, Ohlsson A, Halliday H, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev 2003;1: doi: 10.1002/14651858.CD002057.
Watterberg KL, Gerdes JS, Gifford KL, Lin HM: Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 1999;104:1258–1263.
Latorre FB, Iacobelli GS, Forziati V, Laforgia N, Esposito L, Mautone A. Early low-fose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. Neonatology 2007;91:217–221.
Watterberg KL, Shaffer ML, Mishefske MJ, Leach CL, Mammel MC, Couser RJ. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 2007; 120: 40–48.
Rademaker KJ, Uiterwaal CSPM, Groenendaal F, Uniken Venema MMAT, van Bel F, Beek FJ. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm born children. J Pediatr 2007;150:351–357.
Shah P, Ohlsson A. Alpha-1-proteinase inhibitor (a1PI) for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001:CD002775.
Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 2003; 111: 469–476.
Sandberg K, Fellman V, Stigson L, Thiringer K, Hjalmarson O. N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth weight infants. Biol Neonate 2004;86:275–279.
Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A. Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354:2112–2121.
Abman SH. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 2002;87:F15–18.
Primhak RA. Discharge and aftercare in chronic lung disease of the newborn. Semin Neonatol 2003;8:117–118.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2007 Medical Journal of the Rzeszow University
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
